Small Molecule Degraders of Intracellular HIV Proteins as Novel Anti-HIV Therapeutics

细胞内 HIV 蛋白的小分子降解剂作为新型抗 HIV 疗法

• 批准号: 10441708
• 负责人: FANG LIU
• 金额: $ 30万
• 依托单位: ZYMERON CORPORATION
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10441708
• 关键词: Antiviral Agents; Binding; Cell model; Contracts; DNA; Goals; HIV; HIV-1; Libraries; Nucleic Acids; Proteins; RNA; Research; Therapeutic; cytotoxicity; design; nef Protein; novel; small molecule; therapeutic development; therapeutic target

Therapeutic Targeting of Intracellular HIV-1 Proteins or Nucleic Acids: This research topic supports the development of therapeutics which target intracellular HIV proteins or nucleic acids (DNA, RNA) with the goal of inhibiting their function and ultimately HIV replication. The objective of this contract is to design and synthesize compounds that bind to Nef, an HIV accessory protein, which will be screened, selected and validated on their ability to degrade the Nef protein.

细胞内HIV-1蛋白质或核酸的治疗靶向：该研究课题支持靶向细胞内HIV蛋白质或核酸（DNA，RNA）的治疗方法的开发，目的是抑制其功能并最终抑制HIV复制。该合同的目的是设计和合成与Nef结合的化合物，Nef是一种HIV辅助蛋白，将对其降解Nef蛋白的能力进行筛选，选择和验证。